| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1051655028 |
| P356 | DOI | 10.1007/S11883-011-0197-9 |
| P8608 | Fatcat ID | release_fynrw7pazng43ews33sk4rpfnq |
| P698 | PubMed publication ID | 21789573 |
| P5875 | ResearchGate publication ID | 51521600 |
| P2093 | author name string | Sanjay Kaul | |
| George A Diamond | |||
| Ryan P Morrissey | |||
| P2860 | cites work | Statins for the primary prevention of cardiovascular disease | Q24234813 |
| C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study | Q24617734 | ||
| The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials | Q24646234 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins | Q29547856 | ||
| Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study | Q29617822 | ||
| Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials | Q29617910 | ||
| Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines | Q29619614 | ||
| Intensive versus moderate lipid lowering with statins after acute coronary syndromes | Q29619716 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association | Q30080021 | ||
| Stopping at nothing? Some dilemmas of data monitoring in clinical trials | Q31116157 | ||
| From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey | Q33520621 | ||
| Gauging the impact of statins using number needed to treat | Q33882135 | ||
| Statin-associated memory loss: analysis of 60 case reports and review of the literature | Q33967399 | ||
| Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants | Q34123160 | ||
| Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal | Q34123164 | ||
| Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial | Q34778589 | ||
| Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials | Q36665991 | ||
| Early stopping of randomized clinical trials for overt efficacy is problematic | Q37069734 | ||
| Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis | Q37326885 | ||
| Lipid lowering for primary prevention | Q37433033 | ||
| Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis | Q37717921 | ||
| By Jove! What is a clinician to make of JUPITER? | Q37768304 | ||
| Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prev | Q38376809 | ||
| Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis | Q38377634 | ||
| The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels | Q38464974 | ||
| Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). | Q38467359 | ||
| The JUPITER trial: results, controversies, and implications for prevention | Q38469911 | ||
| Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial | Q38473723 | ||
| Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastat | Q38473855 | ||
| The JUPITER Trial: Responding to the Critics | Q42844459 | ||
| Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. | Q44370707 | ||
| The Effect of Bisoprolol on Perioperative Mortality and Myocardial Infarction in High-Risk Patients Undergoing Vascular Surgery | Q56893725 | ||
| Cost-minimization and the number needed to treat in uncomplicated hypertension | Q74673720 | ||
| The cost-effectiveness of rosuvastatin therapy JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin) | Q83395020 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 413-421 | |
| P577 | publication date | 2011-10-01 | |
| P1433 | published in | Current Atherosclerosis Reports | Q20821076 |
| P1476 | title | The JUPITER trial: myth or reality? | |
| P478 | volume | 13 |
Search more.